1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Wesana Health Holdings Inc.
  6. News
  7. Summary
    WESA   CA95081C1059

WESANA HEALTH HOLDINGS INC.

(WESA)
  Report
Delayed CANADIAN NATIONAL STOCK EXCHANGE  -  05/20 03:52:40 pm EDT
0.2000 CAD   -11.11%
05/10Wesana Health Outlines Accelerated Drug Development Pathway
AQ
05/10Wesana Health Holdings Outlines Accelerated Drug Development Pathway
CI
05/05Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Wesana Health Appoints Meghna A. Gaeta as Chief Marketing Officer

01/25/2022 | 07:31am EDT

CHICAGO and TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc.  (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, announced the appointment of Meghna A. Gaeta as Chief Marketing Officer. In this role, she will lead Wesana’s business marketing strategy. 

“Meghna has a proven track record of brand innovation and development strategies,” said Daniel Carcillo, Founder and CEO of Wesana. “As Wesana continues to expand its clinical network, Meghna’s expertise in practice growth and technology driven patient experiences will help to position Wesana as a premiere leader in the mental health care delivery space. We are thrilled to leverage her ability to bridge the gap that too often exists between patients and their care providers.”

Meghna brings more than 18 years of experience in healthcare, operations, and technology marketing for major, consumer-facing brands, such as Twitter and Walgreens. Meghna most recently led a boutique marketing consultancy, working closely with healthcare, retail & start-up tech clients. In this role, she championed innovative technology to increase access to health care and led and developed scaled ecommerce strategies and solutions. Previously, she served as the head of retail marketing, global business marketing & strategy for Twitter. She also played a pivotal role in establishing and growing a first-of-its-kind care model at Walgreens. There she supervised marketing efforts for 100 retail (pilot) clinics at Walgreens drugstores in over 10 major US markets.

“Wesana is at the forefront of transforming mental health services and drug development and doing it in a way that centers the patient experience from start to finish,” said Gaeta. “Having been a long-time advocate for improved mental health services, I see this new opportunity with Wesana as a space where we can take the lead in assuring patients that there is hope for them and that new therapies are coming soon that can help alleviate the pain they are suffering from. I’m looking forward to building on Wesana’s existing success and helping pave the path to effective and more accessible mental health care.”

Meghna holds a Master of Science Degree in Marketing Communications & eCommerce from IIT Stuart School of Business as well as a Bachelor’s Degree in Political Science from Bryn Mawr College. She is currently working toward a Master of Marriage and Family Therapy degree from The Chicago School of Professional Psychology.

Wesana also announces it has retained the services of North Equities, an investor communications and public relations company, to assist the Company to enhance its market awareness, and communications strategy. Under the terms of the North Equities engagement, which is for an initial six-month period, North Equities will be paid US$70,000 for the six-month term in form of 63,927 restricted stock units of the Company.

About Wesana Health

Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.

Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to future partnerships, collaborative research and the focus of the Company’s business. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance regarding the participation in, or success of, partnerships or collaborative research or that the Company will continue its business as described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Readers are encouraged to refer to the Listing Statement filed on Company’s profile on SEDAR at www.sedar.com for information as to the risks and other factors which may affect the Company’s business objectives and strategic plans.

For more information, please contact:
Media Contact:
Izzy Forman
VP, Communications
Email: media@wesanahealth.com

Nick Opich / Annie Graf
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 786-390-2644

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972


Primary Logo


© GlobeNewswire 2022
All news about WESANA HEALTH HOLDINGS INC.
05/10Wesana Health Outlines Accelerated Drug Development Pathway
AQ
05/10Wesana Health Holdings Outlines Accelerated Drug Development Pathway
CI
05/05Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its..
AQ
05/05Wesana Health Holdings Announces Review of Strategic Alternatives of its Clinics and Ot..
CI
05/02Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highligh..
AQ
05/02Wesana Health Holdings Inc. Reports Earnings Results for the Full Year Ended December 3..
CI
04/27Wesana Health to Present Live at KCSA Virtual Investor Conference April 28th
AQ
04/19Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disor..
AQ
04/18Wesana Explores Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
CI
04/18Wesana Health Holdings Inc. announced that it expects to receive CAD 3.7854 million in ..
CI
More news
Financials (USD)
Sales 2022 1,56 M - -
Net income 2022 -21,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,31x
Yield 2022 -
Capitalization 3,16 M 3,16 M -
Capi. / Sales 2022 2,03x
Capi. / Sales 2023 1,15x
Nbr of Employees -
Free-Float 95,0%
Chart WESANA HEALTH HOLDINGS INC.
Duration : Period :
Wesana Health Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,16 $
Average target price 3,09 $
Spread / Average Target 1 884%
EPS Revisions
Managers and Directors
Daniel Carcillo Chief Executive Officer & Director
Zed Wang Chief Financial Officer & Secretary
Chad Bronstein Executive Chairman
Mark Wingertzahn Chief Scientific Officer
Mitchell Kahn Director
Sector and Competitors
1st jan.Capi. (M$)
WESANA HEALTH HOLDINGS INC.-86.01%3
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567